942143-08-0

Basic information

• Product Name: (R)-tert-butyl 3-(3-methylbenzoyl)piperidine-1-carboxylate
• Synonyms: (R)-tert-butyl 3-(3-methylbenzoyl)piperidine-1-carboxylate
• CAS NO: 942143-08-0
• Molecular Weight: 303.401
• Mol File: 942143-08-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (R)-tert-butyl 3-(3-methylbenzoyl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-tert-butyl 3-(3-methylbenzoyl)piperidine-1-carboxylate(942143-08-0)
• EPA Substance Registry System: (R)-tert-butyl 3-(3-methylbenzoyl)piperidine-1-carboxylate(942143-08-0)

Safety Data

• Hazardous Substances Data: 942143-08-0(Hazardous Substances Data)

Upstream product

• 884510-86-5 (R)-tert-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate 
• 591-17-3 meta-bromotoluene 
• 10325-82-3 m-tolyllithium 

Downstream Products

• 942143-09-1 (R)-tert-butyl 3-((S)-hydroxy(m-tolyl)methyl)piperidine-1-carboxylate 
• 1177419-62-3 C₂₃H₃₇NO₄ 
• 1207444-61-8 C₁₈H₂₇NO₃ 

Relevant articles and documents

Optimization of orally bioavailable alkyl amine renin inhibitors

Structure-guided drug design led to new alkylamine renin inhibitors with improved in vitro and in vivo potency. Lead compound 21a, has an IC50 of 0.83 nM for the inhibition of human renin in plasma (PRA). Oral administration of 21a at 10 mg/kg

ASPARTIC PROTEASE INHIBITORS

The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.